Resultados da busca - Ana Maria Gonzalez-Angulo

CÁNCER DE MAMA TRIPLE RECEPTOR NEGATIVO por JULIO PEGUERO SÁNCHEZ-NAVARRO, ANA MARÍA GONZÁLEZ-ANGULO

Obter o texto integral

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer por Natalia Paez Arango, Erkan Yuca, Ming Zhao, Kurt W. Evans, Stephen Scott, Charissa Kim, Ana Maria Gonzalez-Angulo, Filip Janku, Naoto T. Ueno, Debu Tripathy, Argun Akcakanat, Aung Naing, Funda Meric-Bernstam

Obter o texto integral

The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer. por Young Kwang Chae, Debora de Melo Gagliato, Sachin Gopalkrishna Pai, Benedito Carneiro, Nisha Mohindra, Francis Joseph Giles, Praveen Ramakrishnan-Geethakumari, Joohyuk Sohn, Shuying Liu, Huiqin Chen, Naoto Ueno, Gabriel Hortobagyi, Ana Maria Gonzalez-Angulo

Obter o texto integral

Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. por Priscilla F McAuliffe, Kurt W Evans, Argun Akcakanat, Ken Chen, Xiaofeng Zheng, Hao Zhao, Agda Karina Eterovic, Takafumi Sangai, Ashley M Holder, Chandeshwar Sharma, Huiqin Chen, Kim-Anh Do, Emily Tarco, Mihai Gagea, Katherine A Naff, Aysegul Sahin, Asha S Multani, Dalliah M Black, Elizabeth A Mittendorf, Isabelle Bedrosian, Gordon B Mills, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam

Obter o texto integral

Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. por Priscilla F McAuliffe, Kurt W Evans, Argun Akcakanat, Ken Chen, Xiaofeng Zheng, Hao Zhao, Agda Karina Eterovic, Takafumi Sangai, Ashley M Holder, Chandeshwar Sharma, Huiqin Chen, Kim-Anh Do, Emily Tarco, Mihai Gagea, Katherine A Naff, Aysegul Sahin, Asha S Multani, Dalliah M Black, Elizabeth A Mittendorf, Isabelle Bedrosian, Gordon B Mills, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam

Obter o texto integral

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation por Yan Xing, Nancy U. Lin, Matthew A. Maurer, Huiqin Chen, Armeen Mahvash, Aysegul Sahin, Argun Akcakanat, Yisheng Li, Vandana Abramson, Jennifer Litton, Mariana Chavez-MacGregor, Vicente Valero, Sarina A. Piha-Paul, David Hong, Kim-Anh Do, Emily Tarco, Dianna Riall, Agda Karina Eterovic, Gerburg M. Wulf, Lewis C. Cantley, Gordon B. Mills, L. Austin Doyle, Eric Winer, Gabriel N. Hortobagyi, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam

Obter o texto integral